License international

UCB to license its AI technology that improves osteoporosis identification to ImageBiopsy Lab

BRUSSELS and ATLANTA, 20 October 2021 / PRNewswire / – UCB today announced, on World Osteoporosis Day 2021, the strategic licensing of artificial intelligence (AI) -based fracture identification technology ), BoneBot, to ImageBiopsy Lab to bring the new identification tool into clinical practice by 2023. Radiology AI’s solution will examine CT scans for the presence of “silent” or asymptomatic fractures in the spine that could otherwise go unnoticed and unreported.

“As the digitalization of health increases, the potential for using AI to improve care for many diseases, including osteoporosis, is also increasing. The number one risk factor for fragility fractures is a previous fracture. Identifying and appropriately treating patients who have already suffered a vertebral fracture is therefore essential to ensure that patients can continue to live their lives to the fullest and avoid further fractures, ”said Emmanuel Caeymaex, Executive Vice President of Solutions at immunology and US lead at UCB. “In collaboration with expert clinicians, UCB has developed a deep learning computer model capable of detecting vertebral compression fractures on CT scans. Partnering with a leading musculoskeletal radiology (MSK) AI company will ensure this technology can be integrated into clinical care. ”

“Our ambition is to support the more than 9 million patients worldwide who suffer from a fragility fracture due to osteoporosis each year by helping to identify the patients most at risk. Strategic partnerships and investments with those with the technology and data capabilities can drive our transformation in the most effective way possible. We are excited to be working with ImageBiopsy Lab to launch this important technology. “

Osteoporosis affects approximately 200 million people worldwide1, resulting in 9 million fragility fractures each year, the most common type being vertebral fractures.2.3

“Underreporting in CT scans and the resulting under-treatment of vertebral fractures remains a real challenge for health systems around the world, but this can be improved by standard classification and a clearer path to care.” , said Bo Abrahamsen, endocrinologist and professor of musculoskeletal epidemiology. “Although CT scans performed for other purposes have the potential to identify vertebral fractures, CT scans containing vertebral fractures are often not evaluated with this in mind, given the high time constraints for radiologists. There must be a quick, simple and intuitive way for vertebral fractures to be detected and brought to the attention of the departments responsible for the assessment of osteoporosis. For now, these fractures are hiding in plain sight. We welcome digital innovation that can enable us to perform clinical intervention earlier, ensuring patients get the care they need. “

Founded in 2016, ImageBiopsy Lab has grown into one of the leading AI-backed musculoskeletal imaging diagnostics companies. UCB will license the intellectual property (IP) of BoneBot to ImageBiopsy Lab, which will help bring the technology to market by 2023. ImageBiopsy Lab will then aim to launch globally, including the US, EU and UK.

“On World Osteoporosis Day, when we work together to raise awareness about the prevention, diagnosis and treatment of osteoporosis, we are delighted to announce our involvement in such an important step to osteoporosis care, ”said Richard Ljuhar, CEO of ImageBiopsy Laboratoire. “We look forward to accelerating the impact timeframe of the BoneBot technology which will allow effective clinical intervention earlier and, in turn, could potentially help reduce the co-morbidities associated with osteoporosis.”

About UCB

UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative drugs and solutions to transform the lives of people with severe diseases of the immune system or central nervous system. With more than 8,000 people operating in more than 40 countries, the company generated sales of 5.3 billion euros in 2020. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news and @UCBUSA.

On ImageBiopsy Lab

ImageBiopsy Lab, the ViennaAI solutions developer MSK was founded as a spin-off in late 2016. The company develops and delivers award-winning AI-based software applications that digitize musculoskeletal (MSK) diagnoses on x-rays, providing radiologists and orthopedists rapid quantitative information and standardized reports on findings and measurements relevant to the disease.

Today, ImageBiopsy Lab has offices in the EU and US and brings together an interdisciplinary and international team of physicians, clinical researchers and software experts, sharing the passion to make a lasting and meaningful impact on digital healthcare.

Forward-looking statements – UCB

This press release contains forward-looking statements based on current plans, estimates and beliefs of management. All statements, other than statements of historical fact, are statements that could be considered forward-looking statements, including estimates of income, operating margins, capital expenses, cash, other information. financial, legal, policy, regulatory or clinical expected results and other estimates and results. By their nature, these forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that could cause actual results to differ materially from those that could be implied by these forward-looking statements contained. in this press release. Important factors that could cause such differences include: changes in general economic, business and competitive conditions, inability to obtain necessary regulatory approvals or to obtain them on acceptable terms, costs associated with research and development, changes in the outlook for products in the pipeline or under development by UCB, effects of future court decisions or government investigations, product liability claims, product or product patent protection challenges candidates, changes in laws or regulations, fluctuations in exchange rates, changes or uncertainties in tax laws or the administration of such laws and the hiring and retention of its employees.

UCB is providing this information as of the date of this press release and expressly disclaims any obligation to update any information contained in this press release, either to confirm actual results or to signal a change in its expectations. There is no guarantee that new product candidates in the pipeline will progress towards product approval or that new indications for existing products will be developed and approved. Products or potential products that are the subject of partnerships, joint ventures or licensed collaborations may be subject to differences between the partners. Additionally, UCB or others may discover the safety, side effects, or manufacturing issues of its products after they are released. Additionally, sales may be affected by international and national trends towards containing healthcare and healthcare costs and reimbursement policies imposed by third party payers as well as legislation affecting the pricing and reimbursement of biopharmaceuticals. .

For more information:

Media

Adriaan snauwaert

Global Communications Manager, UCB

T: +32 497 70 23 46

[email protected]

Erica Puntel

Digital communications, UCB

T. 404 938 5359

[email protected]

Investor Relations

Antje Witte,

Investor Relations, UCB

T + 32 2 559 9414

[email protected]

THE REFERENCES

1 Reginster JY, Burlet N. Osteoporosis: An ever increasing prevalence. BONE. 2006; 38 (2 Suppl 1): S4-9

2 Ström O, Borgström F, Kanis JA, et al. Osteoporosis: Burden, Healthcare Delivery and Opportunities in the EU: A Report Prepared in Collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Osteoporos Arch. 2011; 6: 59-155. doi: 10.1007 / s11657-011-0060-1

3 Warriner AH, Patkar NM, Curtis JR, et al. Which fractures are most attributable to osteoporosis ?. J Clin Epidemiol. 2011; 64 (1): 46-53. doi: 10.1016 / j.jclinepi.2010.07.007

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/ucb-to-license-its-ai-technology-that-improves-identification-of-osteoporosis-to-imagebiopsy-lab-301403573.html

SOURCE UCB, Inc.


Source link

LEAVE A RESPONSE

Your email address will not be published. Required fields are marked *